Emerging evidence suggests that GLP1 therapy can: Reduce hepatic fat content, as shown in MRI-PDFF studies Lower markers of liver inflammation and fibrosis Improve insulin sensitivity and metabolic control Although most trials focus on obese or diabetic populations, livercentric endpoints are increasingly evaluated, and benefits appear to extend beyond weight loss alone
By stimulating insulin secretion after meals, these medications help patients with type 2 diabetes maintain healthier blood glucose levels
Wegovy is not recommended in patients with severe gastroparesis Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy
The major clinical trials in the SUSTAIN programme did not identify muscle or joint pain as statistically significant adverse events compared to placebo or comparators
Cardiometabolic Health Track key markers linked to blood sugar control, cardiovascular risk, and metabolic improvements from GLP-1 therapy
How it works Think of each brain neuron as a light bulb and support cells as the components that allow the light bulb to brighten, including the wiring, switch and filament